Seer, Inc.

NASDAQ:SEER

Biotechnology

Healthcare
$1.44 +0.29%

+$0.01 today

Market cap
$80.37M
Beta
1.59
P/E (TTM)
-1.4
EPS (TTM)
-$1.26
52W Low $1.65High $2.41

Volume 0.23M

Average 0.32M

SEER Other Investing Activities

Investing cash flows not reported separately.

Seer, Inc.NASDAQ: SEER

Other Investing Activities · Q1 FY2026 · quarter ended Mar 2026

Other investing activities outflow shrinks to $0

Q1 FY2026 other investing activities was $0, compared with $299K a year earlier. Trailing-twelve-month other investing activities was $133K.

Context

  • Other investing activities amounted to 8.1% of revenue in FY2025, up 5.6 pp from a year earlier.
  • Other investing activities increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly other investing activities holds near $0 or moves back toward the trailing-twelve-month quarterly average of $33.25K.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0+100.0% QoQ
Last fiscal yearDec 2025
-$1.3M-478.7% YoY
LTMMar 2026
$133K-79.3% YoY
Other Investing Activities past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-100.0%——
1 year-478.7%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Other Investing Activities history

USD · from the cash flow

Latest · FY2025
(1.3M) USD
Year-over-year change
-478.7%

Other Investing Activities vs competitors

How SEER compares with its peers on the latest reported figures

  • Peers report in different currencies, so other investing activities is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -79.3% is the 4th highest of 5, against a peer median of +31.0%.
  • Other investing activities amounts to 0.9% of revenue for SEER, versus a peer median of 0.0%.
SEER Competitors
Other Investing Activities for SEER and competitors
Company Period LTM YoY 3-year CAGR% of revenue
KYMRKymera Therapeutics, Inc.LTM Jun 2026$230.34M USD+175.1%-24.4%219.4%
MLYSMineralys Therapeutics, Inc.LTM Jun 2026$200M USD———
STTKShattuck Labs, Inc.LTM Mar 2026$43.48M USD——4347.9%
LYELLyell Immunopharma, Inc.LTM Mar 2026$41.17M USD——132809.7%
SANASana Biotechnology, Inc.LTM Mar 2026$7.59M USD———
MOLNMolecular Partners AGLTM Mar 2026CHF 1.32M CHF-61.1%+51.8%—
ORICORIC Pharmaceuticals, Inc.LTM Mar 2026$223K USD+123.0%——
SEERSeer, Inc.LTM Mar 2026$133K USD-79.3%—0.9%
CGEMCullinan Therapeutics, Inc.LTM Mar 2026$38K USD———
MNOVMediciNova, Inc.LTM Mar 2026$2.9K USD-1564.1%-91.7%0.5%
PHVSPharvaris N.V.LTM Sep 2026€0 EUR———
NRIXNurix Therapeutics, Inc.LTM Aug 2026$0 USD——0.0%
GLUEMonte Rosa Therapeutics, Inc.LTM Mar 2026$0 USD——0.0%
CCCCC4 Therapeutics, Inc.LTM Mar 2026$0 USD——0.0%
PEPGPepGen Inc.LTM Mar 2026$0 USD———
QSIQuantum-Si incorporatedLTM Mar 2026$0 USD——0.0%
ANTXAN2 Therapeutics, Inc.LTM Mar 2026$0 USD———
FHTXFoghorn Therapeutics Inc.LTM Mar 2026$0 USD——0.0%
NKTXNkarta, Inc.LTM Mar 2026$0 USD———
Peer median (excluding SEER) —+31.0%-24.4%0.0%

Competitors are the stored peer set for SEER. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(71.17M)(92.97M)(86.28M)(86.6M)(73.6M)
Depreciation & Amortization2.56M3.94M5.58M6.18M7.25M
Deferred Income Tax1.2M0000
Stock-Based Compensation25.93M33.67M34.42M28.21M15.41M
Change in Working Capital(5.87M)(7.09M)(2.72M)(144K)(579K)
Accounts Receivables(2.5M)(2.87M)302K487K277K
Inventory(3.59M)(1.59M)(1.95M)(2.67M)(2.9M)
Accounts Payables1.6M(1.55M)(987K)3.36M1.06M
Other Working Capital(1.38M)(1.07M)(91K)(1.32M)983K
Other Non-Cash Items1.01M1.66M(10.07M)6.25M7.07M
Operating Cash Flow(46.35M)(60.78M)(59.07M)(46.11M)(44.45M)
Capital Expenditures(6.92M)(10.27M)(7.31M)(3.58M)(1.8M)
Acquisitions (Net)163.96M0000
Purchases of Investments(279.96M)(366.27M)(403.09M)(272.93M)(173.17M)
Sales of Investments116M253.65M448.31M342.03M237.81M
Other Investing Activities(163.96M)170K0343K(1.3M)
Investing Cash Flow(170.88M)(122.72M)37.9M65.86M61.55M
Debt Repayment00000
Common Stock Issued102.96M000458K
Common Stock Repurchased(35K)(20K)(13K)(11.82M)(10.2M)
Dividends Paid00000
Other Financing Activities13.71M3.91M465K321K(827K)
Financing Cash Flow116.63M3.89M452K(11.5M)(10.57M)
Effect of Forex Changes00000
Net Change in Cash(100.59M)(179.61M)(20.71M)8.25M6.53M
Free Cash Flow(53.27M)(71.05M)(66.37M)(49.69M)(46.25M)

Seer, Inc.

NASDAQ:SEER

Intrinsic Alpha fair value

Locked

Current Price

$1.44

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.